GoAI
Get started
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc.

MAIA

AMEXHealthcareBiotechnology

Open in GoAI

Previous close

$1.39

+$0.01 · +0.72%

Aug 21, 4:00 PM ET

MAIA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

50

Fair Value

Momentum

45

Neutral

Sentiment

56

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Vlad Vitoc
Listed since
Jul 28, 2022
Employees
13

Market position

Day range

Current $1.39

52-week range

Current $1.39

Open
$1.38
Previous close
$1.38
Volume
379.74K
0.59× average
Average volume
639.89K
Average daily volume
Market cap
84.51M USD
Beta
0.25
Market reference 1
50-day average
$1.3674
+1.65% above average
200-day average
$1.466
-5.18% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-1.6
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−24.27M USD-43.12%

Net income

−22.4M USD+3.69%
Income trends across reported periods−6.14M USD−12.73M USD−19.32M USD−25.92M USDOperating income, FY2021: −7.79M USDOperating income, FY2022: −16.18M USDOperating income, FY2023: −20.18M USDOperating income, FY2024: −16.96M USDOperating income, FY2025: −24.27M USDNet income, FY2021: −12.5M USDNet income, FY2022: −15.77M USDNet income, FY2023: −19.77M USDNet income, FY2024: −23.25M USDNet income, FY2025: −22.4M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −7.79M USD. Operating income FY2022 −16.18M USD. Operating income FY2023 −20.18M USD. Operating income FY2024 −16.96M USD. Operating income FY2025 −24.27M USD. Net income FY2021 −12.5M USD. Net income FY2022 −15.77M USD. Net income FY2023 −19.77M USD. Net income FY2024 −23.25M USD. Net income FY2025 −22.4M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development14.55B USD10.01M USD11.11M USD8.93M USD3.45M USD
Selling, general, and administrative9.72B USD6.95M USD9.07M USD6.14M USD4.29M USD
Operating expenses24.27M USD16.96M USD20.18M USD16.18M USD7.79M USD
Interest income313.95K USD318.37K USD27.63K USD1.87K USD2.01K USD
Interest expense—57 USD—6.97K USD827.54K USD
Operating income−24.27M USD−16.96M USD−20.18M USD−16.18M USD−7.79M USD
Net income−22.4M USD−23.25M USD−19.77M USD−15.77M USD−12.5M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+4.14%
11 comparable reports
Latest EPS result
-0.13
Estimate -0.11 · Miss by 18.18%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.15-0.23-0.31Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 21, 2025: actual -0.17, estimate -0.2, surprise +15.00%, Beat. Q2 2025, reported May 9, 2025: actual -0.16, estimate -0.18, surprise +11.11%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.18, estimate -0.24, surprise +25.00%, Beat. Q4 2025, reported Nov 7, 2025: actual -0.27, estimate -0.19, surprise -42.11%, Miss. Q1 2026, reported Mar 23, 2026: actual -0.08, estimate -0.13, surprise +38.46%, Beat. Q2 2026, reported May 11, 2026: actual -0.14, estimate -0.18, surprise +22.22%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.13, estimate -0.11, surprise -18.18%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate -0.13, surprise —, Comparison unavailable.

MAIA peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding MAIA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.1M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
835.14K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
250.08K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research MAIA

research.disclaimer